Diagnosis and incidence of inherited von Willebrand disease

Current Opinion in Hematology

Volumn 8, Issue 5, 2001, Pages 306-311

  Hambleton, Julie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; DESMOPRESSIN ACETATE; DNA; ESTROGEN; GLYCOPROTEIN; KOATE DVI; POLYMER; PROTEIN; PYROPHOSPHATE; RISTOCETIN; THROMBOCYTE RECEPTOR; VON WILLEBRAND FACTOR;

AGAR GEL ELECTROPHORESIS; BLEEDING TIME; CLINICAL FEATURE; COST; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE MUTATION; GENE SEQUENCE; GENETIC LINKAGE; HUMAN; INCIDENCE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

FEMALE; HEMATOLOGIC TESTS; HUMANS; INCIDENCE; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PREVALENCE; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0034830890     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200109000-00007     Document Type: Review

References (41)

1. Von Willebrand's disease
2. Von Willebrand disease: Pathogenesis, classification and management
3. Molecular genetics of von Willebrand disease
4. Von Willebrand disease
5. Impact, diagnosis and treatment of von Willebrand disease
6. Diagnosis of von Willebrand disease
7. Analysis of von Willebrand factor in platelets of patients with various forms of von Willebrand disease: Is there a clinical relevance?
8. Comparative analysis of type 2b von Willebrand disease mutations: Implications for the mechanism of von Willebrand factor binding to platelets
9. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: Characterization of abnormal vWF/FVIII interaction
10. Von Willebrand disease and quantitative variation in von Willebrand factor
11. The effect of ABO blood group on the diagnosis of von Willebrand disease
12. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase
13. 1 levels in type 1 von Willebrand disease correlate with impaired platelet function in a high shear stress system
14. Epidemiological investigation of the prevalence of von Willebrand's disease
15. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation
16. On the value of menorrhagia as a predictor for coagulation disorders
17. Frequency of inherited bleeding disorders in women with menorrhagia
18. Laboratory testing, diagnosis, and management of von Willebrand disease
19. Characterization of an in vitro platelet function analyzer, PFA-100™
20. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
21. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease
22. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations
23. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100® and vWF:CBA as combined diagnostic strategies
24. Use of ristocetin cofactor activity in the management of von Willebrand disease
25. Determination of the von Willebrand's disease antigen (Factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis
26. Factor VIII-related antigen: Measurement by enzyme immunoassay
27. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: Significance and practical implications
28. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use
29. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease
30. An ELISA test for the binding of von Willebrand antigen to collagen
31. Development of a simple collagen based ELISA assay aids the diagnosis of, and permits sensitive discrimination between type I and type II von Willebrand's disease
32. Von Willebrand's disease: Laboratory investigation using an improved functional assay for von Willebrand factor
33. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrand disease (VWD), and discrimination of VWD subtypes, depends on collagen source
34. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease
35. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor
36. Type 2N von Willebrand disease: Rapid genetic diagnosis of G2811A (R854Q), C2696 (R816W), T2701A (H817Q) and G2823T (C858F)- detection of a novel candidate type 2N mutation: C2810T (R854W)
37. A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib
38. Type 2M:Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets
39. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets
40. Type 2M VWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor
41. Classification of von Willebrand disease: Emerging issues